Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Two new drugs provide startling benefits in the treatment of age-related macular degeneration (AMD). The clinical and cost effectiveness of ranibizumab (Lucentis) was compared to that of bevacizumab (Avastin), which costs up to 100 times less. A cost effectiveness model was developed to assess the cost per quality adjusted life year (QALY) over 10 years. For predominantly classic AMD, the efficacy of bevacizumab relative to ranibizumab would have to be around 40% for the latter to achieve 30 k pounds per QALY, a NICE threshold. Similar but worse results applied to the other main forms of AMD, minimally occult and occult with no classic lesions. The price of ranibizumab would have to be drastically reduced for it to be cost effective. Continued unlicensed use of bevacizumab raises ethical, legal and policy questions. Public pressure may be the most potent weapon in persuading Genentech to license bevacizumab for AMD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522
The Price of Sight — Ranibizumab, Bevacizumab, and the Treatment of Macular Degeneration
Steinbrook, R. (2006) · New England Journal of Medicine · doi:10.1056/nejmp068185 · Cited by 255
Cited by
Anti-vascular endothelial growth factor for neovascular age-related macular degeneration
Solomon, S. D., Lindsley, K., Vedula, S. S., Krzystolik, M. G., & Hawkins, B. S. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005139.pub3 · Cited by 520
Risk factors and biomarkers of age-related macular degeneration
Lambert, N. G., ElShelmani, H., Singh, M. K., Mansergh, F. C., Wride, M. A., Padilla, M., Keegan, D., Hogg, R. E., & Ambati, B. K. (2016) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2016.04.003 · Cited by 351
Rein, D. B. (2009) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2009.58 · Cited by 344
Anti-vascular endothelial growth factor for neovascular age-related macular degeneration
Solomon, S. D., Lindsley, K., Vedula, S. S., Krzystolik, M. G., & Hawkins, B. S. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005139.pub4 · Cited by 271
Principles of pharmacology in the eye
Awwad, S., Mohamed Ahmed, A. H. A., Sharma, G., Heng, J. S., Khaw, P. T., Brocchini, S., & Lockwood, A. (2017) · British Journal of Pharmacology · doi:10.1111/bph.14024 · Cited by 224
“Each injection of ranibizumab (Lucentis®) can cost $2000, whereas bevacizumab (Avastin®) can cost only $50 for each intravitreal (i.v.t.) dose (Raftery et al., 2007).”
Metadata
- Authors
- Raftery, J., Clegg, A., Jones, J., Tan, S. C., & Lotery, A.
- Venue
- British Journal of Ophthalmology
- Publisher
- BMJ
- Published
- 2007-04-12
- Volume
- 91
- Issue
- 9
- Pages
- 1244-1246
- ISSN
- 0007-1161 (ISSN-L)
- OpenAlex
- W2107057433
- Cited by
- 149
- References
- 3
- FWCI
- 14.96
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.